memantine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
adamantane derivatives 1679 19982-08-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • memantine
  • alzantin
  • memantina
  • memantine hydrochloride
  • ebixa
  • namenda
  • maruxa
  • memantine HCl
  • nemdatine
AMANTADINE derivative that has some dopaminergic effects. It has been proposed as an antiparkinson agent.
  • Molecular weight: 179.31
  • Formula: C12H21N
  • CLOGP: 3.03
  • LIPINSKI: 0
  • HAC: 1
  • HDO: 1
  • TPSA: 26.02
  • ALOGS: -3.60
  • ROTB: 0
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
20 mg O

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.32 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Hosey CM, Chan R, Benet LZ
EoM (Fraction excreted unchanged in urine) 48 % Hosey CM, Chan R, Benet LZ
BA (Bioavailability) 99 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
S (Water solubility) 30 mg/mL Bocci G, Oprea TI, Benet LZ
fu (Fraction unbound in plasma) 0.53 % Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 0.354 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 3.034 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 2.317 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 1.169 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 54.250 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 66.100 % High 1
herg hERG pIC50 4.388 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 1.114 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 4.036 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 66.050 % High 1
kinase-safety-class ACVR2B,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,EIF2AK3,ERBB2,GRK2,IRAK4,ITK,MAPK7,NTRK2,PDK2,PDK4,PRKDC,TEK,TGFBR1 21
kinase-selectivity-class AKT2,EIF2AK3 2
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 3.882 High 1
mh-clint Mouse hepatocyte intrinsic clearance 5.070 High 1
mppb Mouse plasma protein binding (% unbound) 38.200 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 4.446 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 1 High 1
pppb Pig plasma protein binding (% unbound) 46.040 % High 1
rh-clint Rat hepatocyte intrinsic clearance 7.345 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 59.990 % High 1
rppb Rat plasma protein binding (% unbound) 71.240 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 924.698 uM High 1

Approvals:

DateAgencyCompanyOrphan
Oct. 16, 2003 FDA FOREST LABS LLC
May 15, 2002 EMA H. Lundbeck A/S

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Fall 337.63 15.58 466 19239 481344 90127398
Agitation 191.58 15.58 140 19565 66958 90541784
Hallucination 182.40 15.58 135 19570 65824 90542918
Somnolence 162.15 15.58 213 19492 208871 90399871
Body tinea 161.08 15.58 45 19660 2103 90606639
Bradycardia 147.88 15.58 132 19573 83715 90525027
Inhibitory drug interaction 139.71 15.58 44 19661 3119 90605623
Infection susceptibility increased 138.30 15.58 46 19659 3880 90604862
Dementia 136.02 15.58 77 19628 23784 90584958
Aggression 122.91 15.58 75 19630 26593 90582149
Amyloid related imaging abnormality-oedema/effusion 119.77 15.58 30 19675 914 90607828
Abnormal behaviour 118.24 15.58 69 19636 22559 90586183
Confusional state 110.74 15.58 253 19452 385952 90222790
Myoclonus 109.64 15.58 62 19643 19106 90589636
Glucose tolerance impaired 106.53 15.58 46 19659 7939 90600803
Poor quality sleep 100.07 15.58 64 19641 24629 90584113
Encephalopathy 95.80 15.58 80 19625 46364 90562378
Psychomotor hyperactivity 94.34 15.58 49 19656 12764 90595978
Purpura 85.05 15.58 48 19657 14730 90594012
Impaired quality of life 81.63 15.58 55 19650 23089 90585653
Disorientation 80.82 15.58 71 19634 44043 90564699
Amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits 78.51 15.58 20 19685 653 90608089
Death 77.07 15.58 246 19459 456305 90152437
Delirium 75.67 15.58 103 19602 104256 90504486
Impaired work ability 75.61 15.58 49 19656 19277 90589465
Drug interaction 71.39 15.58 174 19531 276279 90332463
Aphasia 70.71 15.58 65 19640 42747 90565995
Bone density decreased 70.38 15.58 45 19660 17300 90591442
Loss of consciousness 69.67 15.58 116 19589 140122 90468620
Joint swelling 68.97 15.58 13 19692 503287 90105455
Cognitive disorder 66.97 15.58 79 19626 69328 90539414
Seizure 66.34 15.58 119 19586 152510 90456232
Cellulitis 65.99 15.58 90 19615 91247 90517495
Hallucination, visual 65.43 15.58 48 19657 23044 90585698
Hyperlipidaemia 63.51 15.58 47 19658 22869 90585873
Rheumatoid arthritis 63.06 15.58 4 19701 362610 90246132
Sialoadenitis 62.89 15.58 22 19683 2160 90606582
Hyponatraemia 61.75 15.58 107 19598 133431 90475311
Urinary tract infection 60.23 15.58 174 19531 305458 90303284
Syncope 59.66 15.58 105 19600 132558 90476184
Lethargy 59.48 15.58 71 19634 63068 90545674
Delusion 56.38 15.58 36 19669 13804 90594938
Electrocardiogram QT prolonged 56.32 15.58 74 19631 72382 90536360
Arthralgia 55.07 15.58 53 19652 778469 89830273
Systemic lupus erythematosus 54.88 15.58 7 19698 361889 90246853
Accidental overdose 54.79 15.58 47 19658 28226 90580516
Maternal exposure during pregnancy 54.52 15.58 7 19698 360056 90248686
Pneumonia aspiration 54.12 15.58 55 19650 40885 90567857
Dysphagia 53.26 15.58 91 19614 112187 90496555
Depressed level of consciousness 52.99 15.58 72 19633 72712 90536030
Hypernatraemia 52.69 15.58 30 19675 9357 90599385
Oral herpes 51.70 15.58 49 19656 33475 90575267
Arthropathy 51.14 15.58 9 19696 366233 90242509
Infusion related reaction 50.62 15.58 14 19691 416766 90191976
Drug hypersensitivity 50.27 15.58 19 19686 463590 90145152
Inappropriate antidiuretic hormone secretion 49.60 15.58 38 19667 19467 90589275
Skin disorder 47.95 15.58 49 19656 36657 90572085
Immune thrombocytopenia 47.78 15.58 32 19673 13294 90595448
Swelling 47.43 15.58 16 19689 419042 90189700
Altered state of consciousness 46.56 15.58 45 19660 31487 90577255
Dyskinesia 46.33 15.58 48 19657 36486 90572256
Myocardial oedema 45.79 15.58 12 19693 439 90608303
Alopecia 44.87 15.58 26 19679 495045 90113697
Orthostatic hypotension 44.36 15.58 50 19655 41777 90566965
Pain 43.70 15.58 95 19610 996246 89612496
Anxiety disorder 42.59 15.58 21 19684 4901 90603841
Speech disorder 42.50 15.58 51 19654 45534 90563208
Pulmonary embolism 42.21 15.58 90 19615 130730 90478012
Electrocardiogram PR prolongation 42.19 15.58 13 19692 857 90607885
Hepatic enzyme increased 42.18 15.58 13 19692 360723 90248019
Neuroleptic malignant syndrome 41.91 15.58 31 19674 15065 90593677
Hypersensitivity 41.03 15.58 24 19681 454653 90154089
Product adhesion issue 38.81 15.58 20 19685 5122 90603620
Intestinal pseudo-obstruction 38.48 15.58 13 19692 1150 90607592
Psoriatic arthropathy 38.28 15.58 3 19702 228332 90380410
Abdominal discomfort 37.95 15.58 29 19676 477299 90131443
Chorea 37.77 15.58 15 19690 2095 90606647
Metastatic neoplasm 37.13 15.58 19 19686 4796 90603946
Sedation 37.12 15.58 49 19656 48122 90560620
Dehydration 36.62 15.58 109 19596 194338 90414404
Urinary retention 36.46 15.58 43 19662 37701 90571041
Balance disorder 36.30 15.58 71 19634 97009 90511733
Product administration interrupted 35.46 15.58 26 19679 12466 90596276
Lower respiratory tract infection 35.32 15.58 6 19699 250653 90358089
Muscle rigidity 34.47 15.58 27 19678 14282 90594460
Cerebral haemorrhage 34.46 15.58 40 19665 34482 90574260
Irritable bowel syndrome 34.02 15.58 3 19702 207445 90401297
Fibromyalgia 33.78 15.58 3 19702 206266 90402476
Stomatitis 33.76 15.58 9 19696 274689 90334053
Lack of spontaneous speech 33.68 15.58 8 19697 194 90608548
Exposure during pregnancy 32.95 15.58 6 19699 238404 90370338
Tremor 32.86 15.58 90 19615 153083 90455659
Cataract 32.31 15.58 57 19648 72035 90536707
Immobile 32.07 15.58 19 19686 6379 90602363
Behaviour disorder 32.05 15.58 17 19688 4618 90604124
Nasopharyngitis 32.01 15.58 25 19680 407079 90201663
Disturbance in attention 31.88 15.58 45 19660 47064 90561678
Akathisia 31.17 15.58 23 19682 11136 90597606
Dystonia 30.65 15.58 27 19678 16792 90591950
Parkinsonism 30.60 15.58 25 19680 14040 90594702
Wound 28.75 15.58 15 19690 302965 90305777
Irritability 28.60 15.58 37 19668 35625 90573117
Sinusitis 28.35 15.58 20 19685 343068 90265674
Incoherent 28.19 15.58 16 19689 4961 90603781
Emotional poverty 28.18 15.58 8 19697 396 90608346
Posture abnormal 27.81 15.58 13 19692 2698 90606044
Hip fracture 27.60 15.58 35 19670 33042 90575700
Therapeutic product effect decreased 27.45 15.58 13 19692 277558 90331184
Extrapyramidal disorder 27.39 15.58 25 19680 16278 90592464
Blood cholesterol increased 27.15 15.58 6 19699 208006 90400736
Ill-defined disorder 27.00 15.58 4 19701 184887 90423855
Herpes zoster 27.00 15.58 62 19643 94582 90514160
Discomfort 26.90 15.58 13 19692 274322 90334420
Dermatitis atopic 26.50 15.58 29 19676 23443 90585299
Akinesia 26.48 15.58 11 19694 1725 90607017
Type 2 diabetes mellitus 26.25 15.58 6 19699 203238 90405504
Head injury 24.45 15.58 32 19673 31156 90577586
Infection 23.99 15.58 26 19679 362068 90246674
Serotonin syndrome 23.89 15.58 35 19670 37852 90570890
Cerebral atrophy 23.78 15.58 15 19690 5631 90603111
Sopor 23.67 15.58 28 19677 24616 90584126
Abdominal pain upper 23.04 15.58 23 19682 332651 90276091
Drug ineffective for unapproved indication 22.82 15.58 47 19658 66597 90542145
Restlessness 22.52 15.58 33 19672 35687 90573055
Contraindicated product administered 22.32 15.58 22 19683 320117 90288625
Myopic chorioretinal degeneration 22.30 15.58 3 19702 0 90608742
Unresponsive to stimuli 22.30 15.58 34 19671 38087 90570655
Blood creatine phosphokinase increased 22.28 15.58 32 19673 33991 90574751
Wheezing 22.26 15.58 12 19693 238068 90370674
Therapeutic drug monitoring analysis not performed 22.24 15.58 9 19696 1320 90607422
Pleurothotonus 22.20 15.58 9 19696 1326 90607416
Metastases to central nervous system 22.15 15.58 23 19682 17519 90591223
Febrile neutropenia 21.84 15.58 4 19701 158345 90450397
Device pacing issue 21.78 15.58 5 19700 104 90608638
Gait disturbance 21.77 15.58 113 19592 260383 90348359
Dizziness 21.56 15.58 209 19496 589075 90019667
Schizophrenia 21.48 15.58 21 19684 14893 90593849
Drug-device interaction 21.35 15.58 5 19700 114 90608628
Pain in extremity 21.33 15.58 41 19664 450488 90158254
Floppy iris syndrome 21.22 15.58 5 19700 117 90608625
Osteoarthritis 21.22 15.58 8 19697 195722 90413020
Gastrointestinal disorder 21.14 15.58 15 19690 256672 90352070
Eye haematoma 21.02 15.58 5 19700 122 90608620
Drug intolerance 20.96 15.58 41 19664 447550 90161192
Apathy 20.67 15.58 18 19687 11022 90597720
Failure to thrive 20.54 15.58 16 19689 8395 90600347
Vitamin D deficiency 20.36 15.58 22 19683 17534 90591208
Liver injury 20.18 15.58 6 19699 170561 90438181
Aptyalism 20.04 15.58 7 19698 684 90608058
Retinopathy of prematurity 19.89 15.58 6 19699 368 90608374
Anaemia neonatal 19.87 15.58 6 19699 369 90608373
Arthritis 19.59 15.58 6 19699 167309 90441433
Diabetic hyperosmolar coma 19.55 15.58 6 19699 390 90608352
Hypophagia 19.55 15.58 31 19674 35906 90572836
Pemphigoid 19.54 15.58 16 19689 9010 90599732
Haemorrhagic stroke 19.53 15.58 14 19691 6482 90602260
Bundle branch block right 19.32 15.58 13 19692 5440 90603302
Stupor 19.26 15.58 13 19692 5469 90603273
Wrong patient received product 19.21 15.58 11 19694 3466 90605276
Lung neoplasm malignant 19.17 15.58 25 19680 24248 90584494
Rash 18.92 15.58 99 19606 796001 89812741
Cerebral infarction 18.88 15.58 26 19679 26570 90582172
Oroantral fistula 18.77 15.58 5 19700 195 90608547
Abdominal pain 18.74 15.58 36 19669 395685 90213057
Rhabdomyolysis 18.56 15.58 37 19668 51219 90557523
Substance-induced psychotic disorder 18.23 15.58 10 19695 2902 90605840
Inflammation 18.22 15.58 8 19697 178584 90430158
Decreased appetite 18.16 15.58 142 19563 376398 90232344
Iron deficiency anaemia 18.12 15.58 24 19681 23638 90585104
Personality change 18.04 15.58 14 19691 7307 90601435
Urticaria 18.03 15.58 25 19680 312709 90296033
Dyspnoea 18.02 15.58 115 19590 880840 89727902
Drowning 17.96 15.58 6 19699 513 90608229
Subdural haematoma 17.82 15.58 20 19685 16625 90592117
Musculoskeletal stiffness 17.81 15.58 23 19682 296509 90312233
Decubitus ulcer 17.70 15.58 17 19688 11796 90596946
Incontinence 17.66 15.58 18 19687 13417 90595325
Asthma 17.63 15.58 16 19689 242144 90366598
Angina pectoris 17.59 15.58 31 19674 39129 90569613
Femur fracture 17.58 15.58 34 19671 46048 90562694
Withdrawal syndrome 17.48 15.58 23 19682 22501 90586241
Generalised tonic-clonic seizure 17.48 15.58 29 19676 34874 90573868
Intentional product use issue 17.44 15.58 13 19692 216879 90391863
Dropped head syndrome 17.38 15.58 5 19700 260 90608482
Non-24-hour sleep-wake disorder 17.28 15.58 3 19702 13 90608729
Moaning 17.24 15.58 7 19698 1036 90607706
Blister 17.23 15.58 18 19687 254980 90353762
Injury 16.96 15.58 11 19694 197338 90411404
Bursitis 16.77 15.58 4 19701 131650 90477092
Lung disorder 16.45 15.58 6 19699 149877 90458865
Insomnia 16.21 15.58 126 19579 333348 90275394
Psoriasis 16.08 15.58 6 19699 147748 90460994
Coma 15.88 15.58 43 19662 72589 90536153
Haemorrhoids 15.88 15.58 24 19681 26678 90582064
Mood altered 15.68 15.58 19 19686 17125 90591617
Accidental exposure to product by child 15.58 15.58 7 19698 1326 90607416

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hallucination 266.47 16.10 192 14359 57315 42549469
Fall 199.84 16.10 316 14235 234204 42372580
Confusional state 165.38 16.10 242 14309 167355 42439429
Dementia 157.10 16.10 87 14464 16393 42590391
Echolalia 116.66 16.10 27 14524 362 42606422
Delirium 113.26 16.10 113 14438 52406 42554378
Bradycardia 110.71 16.10 141 14410 85343 42521441
Abnormal behaviour 105.91 16.10 81 14470 26370 42580414
Amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits 100.71 16.10 27 14524 678 42606106
Aggression 97.01 16.10 96 14455 44067 42562717
Somnolence 86.78 16.10 165 14386 140940 42465844
Death 83.41 16.10 349 14202 470836 42135948
Agitation 83.08 16.10 106 14445 64208 42542576
Amyloid related imaging abnormality-oedema/effusion 82.23 16.10 23 14528 679 42606105
Delusion 79.28 16.10 54 14497 14680 42592104
Pleurothotonus 73.90 16.10 24 14527 1187 42605597
Gait disturbance 68.27 16.10 121 14430 97879 42508905
Sopor 63.11 16.10 45 14506 13157 42593627
Orthostatic hypotension 60.79 16.10 63 14488 30507 42576277
Eosinophilic pleural effusion 48.50 16.10 13 14538 326 42606458
Condition aggravated 48.11 16.10 196 14355 260558 42346226
Mental status changes 47.53 16.10 65 14486 42050 42564734
Hallucination, visual 44.84 16.10 45 14506 20975 42585809
Product adhesion issue 44.02 16.10 18 14533 1721 42605063
Pneumonia aspiration 43.07 16.10 68 14483 50010 42556774
Febrile neutropenia 41.08 16.10 7 14544 185696 42421088
Trifascicular block 39.28 16.10 9 14542 115 42606669
Spur cell anaemia 39.25 16.10 8 14543 56 42606728
Memory impairment 38.85 16.10 65 14486 50157 42556627
Product administration interrupted 38.69 16.10 23 14528 4943 42601841
Foaming at mouth 38.02 16.10 14 14537 1010 42605774
Prescribed underdose 37.90 16.10 30 14521 10252 42596532
Psychomotor hyperactivity 36.22 16.10 30 14521 10928 42595856
Dysphagia 33.95 16.10 76 14475 72643 42534141
Bradyarrhythmia 33.63 16.10 17 14534 2658 42604126
Hyporesponsive to stimuli 32.43 16.10 14 14537 1532 42605252
Dementia with Lewy bodies 32.38 16.10 12 14539 881 42605903
Atrioventricular block 31.11 16.10 26 14525 9589 42597195
Loss of consciousness 30.92 16.10 85 14466 92269 42514515
Sedation 29.89 16.10 44 14507 30431 42576353
Subdural haematoma 29.62 16.10 38 14513 23100 42583684
Balance disorder 29.55 16.10 56 14495 47589 42559195
Urinary tract infection 29.00 16.10 87 14464 99197 42507587
Syncope 28.94 16.10 87 14464 99319 42507465
Cognitive disorder 28.82 16.10 46 14505 34126 42572658
Gait inability 28.45 16.10 37 14514 22796 42583988
Hallucination, auditory 28.40 16.10 30 14521 14834 42591950
Tremor 28.37 16.10 85 14466 96844 42509940
Electrocardiogram QT prolonged 28.08 16.10 55 14496 47890 42558894
Mixed dementia 27.69 16.10 8 14543 266 42606518
Bifascicular block 26.66 16.10 8 14543 304 42606480
Asthenia 26.41 16.10 175 14376 280618 42326166
Speech disorder 25.66 16.10 40 14511 29081 42577703
Product name confusion 25.48 16.10 6 14545 87 42606697
Dyskinesia 25.39 16.10 37 14514 25353 42581431
Myoclonus 25.01 16.10 30 14521 17035 42589749
Hypophagia 23.71 16.10 37 14514 26919 42579865
Medication error 23.12 16.10 41 14510 33113 42573671
Neuroleptic malignant syndrome 22.51 16.10 32 14519 21440 42585344
Inappropriate antidiuretic hormone secretion 22.49 16.10 28 14523 16513 42590271
Hip fracture 21.94 16.10 25 14526 13447 42593337
Anaemia 21.80 16.10 39 14512 280239 42326545
Sinus bradycardia 21.59 16.10 26 14525 14827 42591957
Rhythm idioventricular 21.56 16.10 7 14544 346 42606438
Mania 21.43 16.10 22 14529 10525 42596259
Neutropenia 21.31 16.10 22 14529 199409 42407375
Depressed level of consciousness 21.12 16.10 49 14502 47921 42558863
Urinary incontinence 20.84 16.10 31 14520 21637 42585147
Conduction disorder 20.50 16.10 12 14539 2506 42604278
Hypersomnia 20.29 16.10 25 14526 14593 42592191
Hypertensive crisis 20.22 16.10 21 14530 10185 42596599
Ataxia 19.88 16.10 26 14525 16099 42590685
Nonspecific reaction 19.62 16.10 10 14541 1591 42605193
Atrioventricular block second degree 19.38 16.10 14 14537 4173 42602611
Hallucination, olfactory 19.15 16.10 6 14545 264 42606520
Motor dysfunction 18.41 16.10 18 14533 8128 42598656
Catatonia 18.40 16.10 16 14535 6223 42600561
Marasmus 18.39 16.10 8 14543 891 42605893
Disturbance in attention 18.38 16.10 35 14516 29831 42576953
Product dose omission issue 18.14 16.10 102 14449 154263 42452521
Disorientation 18.06 16.10 39 14512 36350 42570434
Decreased appetite 17.89 16.10 120 14431 193017 42413767
Thought blocking 17.89 16.10 5 14546 147 42606637
Dysstasia 17.82 16.10 23 14528 14063 42592721
Drug hypersensitivity 17.56 16.10 6 14545 99383 42507401
Illusion 17.36 16.10 8 14543 1021 42605763
Accidental overdose 17.19 16.10 33 14518 28297 42578487
Decreased activity 16.85 16.10 14 14537 5121 42601663
Behaviour disorder 16.71 16.10 16 14535 7038 42599746
Therapeutic response unexpected 16.66 16.10 20 14531 11361 42595423
Altered state of consciousness 16.44 16.10 33 14518 29226 42577558
Paranoia 16.35 16.10 22 14529 14004 42592780
Cerebral infarction 16.16 16.10 34 14517 31135 42575649
Parkinsonism 16.10 16.10 19 14532 10604 42596180

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Fall 436.88 14.68 660 28817 602822 109957000
Hallucination 347.42 14.68 256 29221 101176 110458646
Bradycardia 248.67 14.68 254 29223 155263 110404559
Agitation 240.17 14.68 216 29261 112835 110446987
Confusional state 215.68 14.68 420 29057 468260 110091562
Dementia 212.50 14.68 122 29355 31551 110528271
Aggression 210.65 14.68 153 29324 59057 110500765
Somnolence 203.96 14.68 318 29159 297131 110262691
Death 185.65 14.68 504 28973 698365 109861457
Amyloid related imaging abnormality-oedema/effusion 184.69 14.68 49 29428 1526 110558296
Abnormal behaviour 171.89 14.68 115 29362 38924 110520898
Amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits 167.36 14.68 44 29433 1322 110558500
Body tinea 148.32 14.68 44 29433 2071 110557751
Myoclonus 135.24 14.68 93 29384 32905 110526917
Delirium 133.36 14.68 172 29305 134853 110424969
Delusion 124.29 14.68 78 29399 23677 110536145
Infection susceptibility increased 120.35 14.68 45 29432 4353 110555469
Psychomotor hyperactivity 117.33 14.68 71 29406 20206 110539616
Echolalia 113.94 14.68 27 29450 524 110559298
Inhibitory drug interaction 108.19 14.68 43 29434 4904 110554918
Pneumonia aspiration 103.89 14.68 118 29359 81115 110478707
Pleurothotonus 100.41 14.68 34 29443 2464 110557358
Loss of consciousness 94.99 14.68 180 29297 196126 110363696
Orthostatic hypotension 92.91 14.68 101 29376 66148 110493674
Glucose tolerance impaired 85.58 14.68 45 29432 9792 110550030
Poor quality sleep 83.05 14.68 65 29412 28012 110531810
Electrocardiogram QT prolonged 80.86 14.68 121 29356 108839 110450983
Hallucination, visual 80.73 14.68 74 29403 39531 110520291
Syncope 78.07 14.68 169 29308 202367 110357455
Sopor 77.85 14.68 70 29407 36476 110523346
Joint swelling 76.55 14.68 13 29464 442832 110116990
Disorientation 74.43 14.68 93 29384 70578 110489244
Neuroleptic malignant syndrome 74.06 14.68 66 29411 33993 110525829
Drug hypersensitivity 72.85 14.68 16 29461 454074 110105748
Inappropriate antidiuretic hormone secretion 70.46 14.68 64 29413 33787 110526035
Cognitive disorder 70.45 14.68 101 29376 87410 110472412
Arthralgia 67.61 14.68 65 29412 779567 109780255
Gait disturbance 66.97 14.68 194 29283 278014 110281808
Product administration interrupted 66.51 14.68 40 29437 11252 110548570
Drug interaction 66.00 14.68 286 29191 499897 110059925
Rheumatoid arthritis 63.98 14.68 4 29473 299609 110260213
Dysphagia 63.61 14.68 132 29345 153468 110406354
Bone density decreased 62.88 14.68 44 29433 15998 110543824
Depressed level of consciousness 61.93 14.68 109 29368 112169 110447653
Dyskinesia 61.17 14.68 72 29405 51374 110508448
Accidental overdose 60.73 14.68 72 29405 51762 110508060
Synovitis 60.56 14.68 3 29474 274089 110285733
Purpura 58.54 14.68 50 29427 24338 110535484
Speech disorder 58.50 14.68 77 29400 61492 110498330
Sialoadenitis 57.64 14.68 23 29454 2650 110557172
Encephalopathy 57.27 14.68 88 29389 80967 110478855
Aphasia 56.39 14.68 74 29403 58923 110500899
Mental status changes 55.70 14.68 84 29393 76038 110483784
Impaired quality of life 53.36 14.68 52 29425 29965 110529857
Sedation 52.56 14.68 78 29399 69605 110490217
Balance disorder 51.61 14.68 103 29374 116457 110443365
Altered state of consciousness 51.58 14.68 70 29407 57556 110502266
Tremor 51.54 14.68 144 29333 202088 110357734
Febrile neutropenia 51.11 14.68 11 29466 316756 110243066
Arthropathy 50.64 14.68 8 29469 287514 110272308
Eosinophilic pleural effusion 50.54 14.68 14 29463 514 110559308
Urinary tract infection 50.43 14.68 196 29281 326086 110233736
Seizure 50.11 14.68 151 29326 221034 110338788
Impaired work ability 49.29 14.68 47 29430 26372 110533450
Lethargy 47.96 14.68 88 29389 93488 110466334
Disturbance in attention 47.63 14.68 70 29407 61925 110497897
Maternal exposure during pregnancy 47.44 14.68 6 29471 254877 110304945
Hallucination, auditory 45.56 14.68 45 29432 26352 110533470
Hyponatraemia 45.05 14.68 144 29333 217509 110342313
Subdural haematoma 44.97 14.68 52 29425 36402 110523420
Systemic lupus erythematosus 44.96 14.68 7 29470 254331 110305491
Swelling 44.37 14.68 19 29458 351022 110208800
Muscle rigidity 43.41 14.68 42 29435 23989 110535833
Hip fracture 43.13 14.68 50 29427 35101 110524721
Infusion related reaction 43.07 14.68 24 29453 381138 110178684
Behaviour disorder 41.44 14.68 28 29449 9619 110550203
Atrioventricular block 41.32 14.68 35 29442 16842 110542980
Hepatic enzyme increased 41.15 14.68 17 29460 320875 110238947
Cerebral haemorrhage 41.01 14.68 67 29410 64901 110494921
Dementia with Lewy bodies 40.85 14.68 14 29463 1052 110558770
Hyperlipidaemia 40.68 14.68 49 29428 35799 110524023
Cerebral infarction 40.50 14.68 59 29418 51779 110508043
Stomatitis 40.42 14.68 11 29466 270231 110289591
Nasopharyngitis 40.18 14.68 28 29449 394333 110165489
Asthenia 40.00 14.68 317 29160 688682 109871140
Hypophagia 39.82 14.68 59 29418 52567 110507255
Skin disorder 39.73 14.68 53 29424 42860 110516962
Sinus bradycardia 39.68 14.68 44 29433 29439 110530383
Hypernatraemia 39.65 14.68 35 29442 17798 110542024
Failure to thrive 39.22 14.68 31 29446 13543 110546279
Extrapyramidal disorder 38.71 14.68 43 29434 28824 110530998
Parkinsonism 38.62 14.68 38 29439 22149 110537673
Posture abnormal 37.74 14.68 20 29457 4418 110555404
Oral herpes 37.21 14.68 47 29430 36033 110523789
Rash 36.94 14.68 105 29372 820859 109738963
Mania 36.91 14.68 36 29441 20760 110539062
Electrocardiogram PR prolongation 36.78 14.68 15 29462 1828 110557994
Trifascicular block 36.49 14.68 9 29468 208 110559614
Bradyarrhythmia 35.76 14.68 20 29457 4914 110554908
Pain 35.46 14.68 133 29344 954822 109605000
Spur cell anaemia 35.33 14.68 8 29469 126 110559696
Condition aggravated 35.22 14.68 324 29153 734512 109825310
Petit mal epilepsy 35.06 14.68 23 29454 7524 110552298
Alopecia 34.45 14.68 28 29449 364725 110195097
Fibromyalgia 34.43 14.68 3 29474 170906 110388916
Dehydration 33.90 14.68 156 29321 279355 110280467
Atrioventricular block first degree 33.80 14.68 29 29448 14196 110545626
Mixed dementia 33.80 14.68 9 29468 284 110559538
Foaming at mouth 33.77 14.68 15 29462 2255 110557567
Head injury 33.66 14.68 49 29428 42968 110516854
Hypersensitivity 33.44 14.68 35 29442 403963 110155859
Serotonin syndrome 33.34 14.68 58 29419 59095 110500727
Irritable bowel syndrome 32.76 14.68 3 29474 164212 110395610
Therapeutic product effect decreased 31.22 14.68 13 29464 244303 110315519
Cerebral atrophy 31.20 14.68 23 29454 9062 110550760
Irritability 31.12 14.68 50 29427 47759 110512063
Incoherent 30.62 14.68 22 29455 8336 110551486
Hyporesponsive to stimuli 30.46 14.68 15 29462 2845 110556977
Osteoarthritis 30.15 14.68 6 29471 182617 110377205
Lack of spontaneous speech 29.73 14.68 8 29469 263 110559559
Lower respiratory tract infection 29.39 14.68 14 29463 243092 110316730
Illusion 29.01 14.68 13 29464 1994 110557828
Sinusitis 28.99 14.68 22 29455 296666 110263156
Urinary retention 28.96 14.68 60 29417 69623 110490199
Restlessness 28.94 14.68 53 29424 56206 110503616
Tardive dyskinesia 28.89 14.68 26 29451 13553 110546269
Marasmus 27.84 14.68 12 29465 1679 110558143
Immune thrombocytopenia 27.60 14.68 32 29445 22462 110537360
Dyspnoea 27.32 14.68 178 29299 1106694 109453128
Dystonia 27.22 14.68 34 29443 25771 110534051
Product adhesion issue 26.85 14.68 14 29463 2992 110556830
Inflammation 26.84 14.68 9 29468 193229 110366593
Arthritis 26.65 14.68 6 29471 167580 110392242
Exposure during pregnancy 26.61 14.68 6 29471 167418 110392404
Bifascicular block 26.57 14.68 8 29469 396 110559426
Discomfort 26.52 14.68 12 29465 214695 110345127
Asthma 26.51 14.68 17 29460 250274 110309548
Decreased appetite 26.51 14.68 217 29260 475629 110084193
Incontinence 26.22 14.68 27 29450 16608 110543214
Wheezing 26.14 14.68 18 29459 255212 110304610
Chorea 25.89 14.68 14 29463 3221 110556601
Abdominal pain 25.79 14.68 62 29415 512927 110046895
Freezing phenomenon 25.77 14.68 13 29464 2596 110557226
Akathisia 25.58 14.68 27 29450 17086 110542736
Type 2 diabetes mellitus 25.06 14.68 8 29469 177224 110382598
Blood cholesterol increased 24.98 14.68 9 29468 184776 110375046
Hypersomnia 24.97 14.68 34 29443 28027 110531795
Contraindicated product administered 24.78 14.68 18 29459 248249 110311573
Catatonia 24.76 14.68 22 29455 11278 110548544
Blister 24.70 14.68 15 29462 227361 110332461
Psoriasis 24.40 14.68 4 29473 139989 110419833
Bursitis 24.31 14.68 3 29474 129915 110429907
Unresponsive to stimuli 24.28 14.68 53 29424 63737 110496085
Neutropenia 24.25 14.68 39 29438 374581 110185241
Akinesia 24.25 14.68 14 29463 3653 110556169
Hyperglycaemic hyperosmolar nonketotic syndrome 24.02 14.68 13 29464 2996 110556826
Urticaria 23.80 14.68 30 29447 318827 110240995
Abdominal discomfort 23.67 14.68 43 29434 393815 110166007
Superficial siderosis of central nervous system 23.54 14.68 6 29471 159 110559663
Immobile 23.14 14.68 18 29459 7684 110552138
Ataxia 23.13 14.68 34 29443 30074 110529748
Urinary incontinence 22.78 14.68 44 29433 48543 110511279
Liver injury 22.72 14.68 6 29471 150407 110409415
Intestinal pseudo-obstruction 22.69 14.68 13 29464 3343 110556479
Emotional poverty 22.60 14.68 9 29468 1031 110558791
Lung disorder 22.33 14.68 10 29467 180037 110379785
Intentional product use issue 22.21 14.68 20 29457 247886 110311936
Atrioventricular block second degree 22.18 14.68 18 29459 8163 110551659
Myopic chorioretinal degeneration 21.69 14.68 3 29474 0 110559822
Anger 21.60 14.68 26 29451 18981 110540841
Product name confusion 21.51 14.68 6 29471 226 110559596
Generalised tonic-clonic seizure 21.46 14.68 46 29431 54634 110505188
Apathy 21.44 14.68 24 29453 16215 110543607
Pain in extremity 21.36 14.68 63 29414 487055 110072767
Infection 21.35 14.68 40 29437 362160 110197662
Hypothermia 20.63 14.68 30 29447 26272 110533550
Cataract 20.62 14.68 57 29420 79428 110480394
Atrioventricular block complete 20.45 14.68 26 29451 20056 110539766
Medication error 20.24 14.68 68 29409 105298 110454524
Gastrointestinal disorder 19.96 14.68 21 29456 241931 110317891
Drug intolerance 19.74 14.68 50 29427 406462 110153360
Withdrawal syndrome 19.31 14.68 32 29445 31348 110528474
Cellulitis 18.87 14.68 75 29402 125941 110433881
Drug ineffective for unapproved indication 18.56 14.68 65 29412 102773 110457049
Therapeutic response unexpected 18.42 14.68 27 29450 23816 110536006
Dysstasia 18.14 14.68 32 29445 32954 110526868
Obesity 18.14 14.68 4 29473 113347 110446475
Conduction disorder 17.97 14.68 12 29465 4043 110555779
Rhythm idioventricular 17.78 14.68 7 29470 778 110559044
Pemphigoid 17.72 14.68 24 29453 19683 110540139
Decubitus ulcer 17.62 14.68 23 29454 18213 110541609
Neuropsychiatric symptoms 17.53 14.68 8 29469 1280 110558542
Ill-defined disorder 17.52 14.68 10 29467 156843 110402979
Rhabdomyolysis 17.50 14.68 71 29406 120330 110439492
Injury 17.49 14.68 13 29464 177252 110382570
Therapeutic drug monitoring analysis not performed 17.27 14.68 9 29468 1922 110557900
Pruritus 17.27 14.68 88 29389 581472 109978350
Aptyalism 16.95 14.68 7 29470 881 110558941
Abdominal pain upper 16.90 14.68 43 29434 349068 110210754
Paranoia 16.80 14.68 25 29452 22349 110537473
Gastrooesophageal reflux disease 16.75 14.68 14 29463 179962 110379860
Hypertensive crisis 16.56 14.68 26 29451 24346 110535476
Neuropsychological test abnormal 16.32 14.68 3 29474 15 110559807
Electrocardiogram J wave 16.19 14.68 4 29473 93 110559729
Hallucination, olfactory 15.97 14.68 6 29471 588 110559234
Femur fracture 15.86 14.68 36 29441 44433 110515389
Eye haematoma 15.76 14.68 5 29472 295 110559527
Oesophageal dilatation 15.75 14.68 6 29471 611 110559211
C-reactive protein increased 15.74 14.68 21 29456 217898 110341924
Blood creatine phosphokinase increased 15.70 14.68 49 29428 73028 110486794
Wound 15.55 14.68 24 29453 234413 110325409
Neurotransmitter level altered 15.46 14.68 3 29474 21 110559801
Drug-device interaction 15.06 14.68 4 29473 125 110559697
Musculoskeletal pain 14.97 14.68 16 29461 183007 110376815
Hypercholesterolaemia 14.96 14.68 3 29474 90834 110468988
Floppy iris syndrome 14.95 14.68 5 29472 349 110559473
Ileus paralytic 14.91 14.68 17 29460 11720 110548102
Pulmonary embolism 14.84 14.68 103 29374 214371 110345451

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N06DA52 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTI-DEMENTIA DRUGS
Anticholinesterases
ATC N06DA53 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTI-DEMENTIA DRUGS
Anticholinesterases
ATC N06DX01 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTI-DEMENTIA DRUGS
Other anti-dementia drugs
FDA MoA N0000020015 NMDA Receptor Antagonists
MeSH PA D000978 Antiparkinson Agents
MeSH PA D015259 Dopamine Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018691 Excitatory Amino Acid Antagonists
MeSH PA D018726 Anti-Dyskinesia Agents
FDA EPC N0000175745 N-methyl-D-aspartate Receptor Antagonist
CHEBI has role CHEBI:35469 antidepressant
CHEBI has role CHEBI:35474 anxiolytic drug
CHEBI has role CHEBI:35476 antipsychotic agent
CHEBI has role CHEBI:35480 analgesic
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35705 immunosuppressive agent
CHEBI has role CHEBI:39456 antiglaucoma drug
CHEBI has role CHEBI:48407 antiparkinson drug
CHEBI has role CHEBI:48560 dopaminergic agent
CHEBI has role CHEBI:60643 NMDA receptor antagonist
CHEBI has role CHEBI:63726 neuroprotective agent
CHEBI has role CHEBI:74518 anti-obesity agent
CHEBI has role CHEBI:75835 anti-anaemic agent

Related Drugs by ATC class:

N06DA Anticholinesterases 5 drugs
donepezilgalantamineipidacrinerivastigminetacrine
N06DX Other anti-dementia drugs 3 drugs
aducanumabdonanemab-azbtlecanemab

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Moderate to Severe Alzheimer's Type Dementia indication
Acute nephropathy contraindication 58574008
Impaired renal function disorder contraindication 197663003
Disease of liver contraindication 235856003 DOID:409




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.37 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
14MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** NAMENDA XR ABBVIE N022525 June 21, 2010 DISCN CAPSULE, EXTENDED RELEASE ORAL 8039009 March 24, 2029 TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
21MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** NAMENDA XR ABBVIE N022525 June 21, 2010 DISCN CAPSULE, EXTENDED RELEASE ORAL 8039009 March 24, 2029 TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
28MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** NAMENDA XR ABBVIE N022525 June 21, 2010 DISCN CAPSULE, EXTENDED RELEASE ORAL 8039009 March 24, 2029 TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
7MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** NAMENDA XR ABBVIE N022525 June 21, 2010 DISCN CAPSULE, EXTENDED RELEASE ORAL 8039009 March 24, 2029 TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;14MG NAMZARIC ABBVIE N206439 Dec. 23, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 8039009 March 24, 2029 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;21MG NAMZARIC ABBVIE N206439 July 18, 2016 RX CAPSULE, EXTENDED RELEASE ORAL 8039009 March 24, 2029 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;28MG NAMZARIC ABBVIE N206439 Dec. 23, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 8039009 March 24, 2029 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;7MG NAMZARIC ABBVIE N206439 July 18, 2016 RX CAPSULE, EXTENDED RELEASE ORAL 8039009 March 24, 2029 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;14MG NAMZARIC ABBVIE N206439 Dec. 23, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 8058291 Dec. 5, 2029 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;21MG NAMZARIC ABBVIE N206439 July 18, 2016 RX CAPSULE, EXTENDED RELEASE ORAL 8058291 Dec. 5, 2029 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;28MG NAMZARIC ABBVIE N206439 Dec. 23, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 8058291 Dec. 5, 2029 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;7MG NAMZARIC ABBVIE N206439 July 18, 2016 RX CAPSULE, EXTENDED RELEASE ORAL 8058291 Dec. 5, 2029 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Glutamate receptor ionotropic, NMDA 1 Ion channel NEGATIVE ALLOSTERIC MODULATOR IC50 5.02 CHEMBL CHEMBL
Glutamate receptor ionotropic, NMDA 3A Ion channel NEGATIVE ALLOSTERIC MODULATOR WOMBAT-PK CHEMBL
Glutamate NMDA receptor; GRIN1/GRIN2B Ion channel NEGATIVE ALLOSTERIC MODULATOR IC50 5.26 CHEMBL CHEMBL
Glutamate NMDA receptor; GRIN1/GRIN2A Ion channel NEGATIVE ALLOSTERIC MODULATOR IC50 9.02 CHEMBL CHEMBL
Solute carrier family 22 member 1 Transporter IC50 4.57 CHEMBL
Acetylcholinesterase Enzyme IC50 8.31 CHEMBL
5-hydroxytryptamine receptor 3A Ion channel WOMBAT-PK
Glutamate receptor ionotropic, NMDA 2C Ion channel Ki 6.15 CHEMBL
Glutamate receptor ionotropic, NMDA 1 Ion channel EC50 5.57 CHEMBL

External reference:

IDSource
4021409 VUID
N0000148824 NUI
D04905 KEGG_DRUG
41100-52-1 SECONDARY_CAS_RN
4021409 VANDF
C0025242 UMLSCUI
CHEBI:64312 CHEBI
377 PDB_CHEM_ID
CHEMBL807 ChEMBL_ID
DB01043 DRUGBANK_ID
CHEMBL1699 ChEMBL_ID
D008559 MESH_DESCRIPTOR_UI
4054 PUBCHEM_CID
3952 INN_ID
4253 IUPHAR_LIGAND_ID
W8O17SJF3T UNII
236685 RXNORM
169783 MMSL
17635 MMSL
203022 MMSL
47628 MMSL
d04899 MMSL
006597 NDDF
006598 NDDF
406457005 SNOMEDCT_US
406458000 SNOMEDCT_US
426610008 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Namzaric HUMAN PRESCRIPTION DRUG LABEL 2 0456-1207 CAPSULE 7 mg ORAL NDA 31 sections
Namzaric HUMAN PRESCRIPTION DRUG LABEL 2 0456-1214 CAPSULE 14 mg ORAL NDA 31 sections
Namzaric HUMAN PRESCRIPTION DRUG LABEL 2 0456-1221 CAPSULE 21 mg ORAL NDA 31 sections
Namzaric HUMAN PRESCRIPTION DRUG LABEL 2 0456-1228 CAPSULE 28 mg ORAL NDA 31 sections
Namenda HUMAN PRESCRIPTION DRUG LABEL 1 0456-3205 TABLET 5 mg ORAL NDA 31 sections
Namenda HUMAN PRESCRIPTION DRUG LABEL 1 0456-3210 TABLET 10 mg ORAL NDA 31 sections
memantine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-3870 TABLET 5 mg ORAL NDA authorized generic 31 sections
memantine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-3875 TABLET 10 mg ORAL NDA authorized generic 31 sections
Memantine HUMAN PRESCRIPTION DRUG LABEL 1 0615-8100 TABLET 10 mg ORAL ANDA 27 sections
Memantine HUMAN PRESCRIPTION DRUG LABEL 1 0615-8192 TABLET 5 mg ORAL ANDA 27 sections
memantine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-8264 CAPSULE, EXTENDED RELEASE 28 mg ORAL ANDA 22 sections
Memantine HUMAN PRESCRIPTION DRUG LABEL 1 0615-8319 TABLET 10 mg ORAL ANDA 26 sections
Memantine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-1112 TABLET, FILM COATED 5 mg ORAL ANDA 30 sections
Memantine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-1113 TABLET, FILM COATED 10 mg ORAL ANDA 30 sections
Memantine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6505 TABLET, FILM COATED 5 mg ORAL ANDA 26 sections
Memantine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6506 TABLET, FILM COATED 10 mg ORAL ANDA 26 sections
memantine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6734 CAPSULE, EXTENDED RELEASE 7 mg ORAL ANDA 22 sections
memantine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6735 CAPSULE, EXTENDED RELEASE 28 mg ORAL ANDA 22 sections
memantine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6736 CAPSULE, EXTENDED RELEASE 14 mg ORAL ANDA 22 sections
memantine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6737 CAPSULE, EXTENDED RELEASE 21 mg ORAL ANDA 22 sections
Memantine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 13925-540 SOLUTION 2 mg ORAL ANDA 30 sections
Memantine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16571-852 CAPSULE, EXTENDED RELEASE 7 mg ORAL ANDA 28 sections
Memantine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16571-853 CAPSULE, EXTENDED RELEASE 14 mg ORAL ANDA 28 sections
Memantine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16571-854 CAPSULE, EXTENDED RELEASE 21 mg ORAL ANDA 28 sections
Memantine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16571-855 CAPSULE, EXTENDED RELEASE 28 mg ORAL ANDA 28 sections
Namenda HUMAN PRESCRIPTION DRUG LABEL 1 21695-169 TABLET 10 mg ORAL NDA 12 sections
Namenda HUMAN PRESCRIPTION DRUG LABEL 1 21695-232 TABLET 5 mg ORAL NDA 12 sections
Memantine Hydrochloride Human Prescription Drug Label 1 27241-070 TABLET 5 mg ORAL ANDA 26 sections
Memantine Hydrochloride Human Prescription Drug Label 1 27241-071 TABLET 10 mg ORAL ANDA 26 sections
Memantine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 29300-171 TABLET, FILM COATED 5 mg ORAL ANDA 23 sections